Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2024-12-27 00:00:00 ET · period of report 2024-12-24 · accession 0000950170-24-140871 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-27 | 2024-12-24 | BBIO | Kumar Neil | CEO, Dir | G - Gift | $0.00 | -4.69M | 211.7K | -96% | $0 | |
| I | 2024-12-27 | 2024-12-24 | BBIO | Kumar Neil | CEO, Dir | G - Gift | $0.00 | +4.69M | 5.70M | +463% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-24 | G | D | 4,685,725 | $0.00 | 211,718 | D By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | — | — | (F1) The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| 2 | Common | Common Stock | 2024-12-24 | G | A | 4,685,725 | $0.00 | 5,698,447 | I | — | — |